{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:33:58Z","timestamp":1789522438696,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.canlet.2019.11.025","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T11:33:59Z","timestamp":1574422439000},"page":"170-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models"],"prefix":"10.1016","volume":"470","author":[{"given":"Bin","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2019.11.025_bib1","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.2174\/092986712800099785","article-title":"ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents","volume":"19","author":"Shurin","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.canlet.2019.11.025_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.11.025_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4614-3146-6_5","article-title":"Mechanisms of immune evasion by gliomas","volume":"746","author":"Rolle","year":"2012","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.canlet.2019.11.025_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fimmu.2013.00116","article-title":"Targeting tregs in malignant brain cancer: overcoming IDO","volume":"4","author":"Wainwright","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2019.11.025_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2019.11.025_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/cdd.2013.75","article-title":"Molecular mechanisms of ATP secretion during immunogenic cell death","volume":"21","author":"Martins","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2019.11.025_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.11.025_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/cdd.2013.84","article-title":"Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments","volume":"21","author":"Inoue","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2019.11.025_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1386829","article-title":"Trial watch: immunogenic cell death induction by anticancer chemotherapeutics","volume":"6","author":"Garg","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2019.11.025_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5301\/tj.5000675","article-title":"The inducers of immunogenic cell death for tumor immunotherapy","volume":"104","author":"Li","year":"2018","journal-title":"Tumori"},{"key":"10.1016\/j.canlet.2019.11.025_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/1389203718666170111123253","article-title":"Emerging roles of calreticulin in cancer: implications for therapy","volume":"19","author":"Venkateswaran","year":"2018","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.canlet.2019.11.025_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2019.11.025_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12601","article-title":"High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair","volume":"280","author":"Bianchi","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2019.11.025_bib14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2019.11.025_bib15","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm.3708","article-title":"Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy","volume":"20","author":"Sistigu","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2019.11.025_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis"},{"key":"10.1016\/j.canlet.2019.11.025_bib17","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.11.025_bib18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00280-016-3152-1","article-title":"The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy","volume":"78","author":"Ahlmann","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2019.11.025_bib19","first-page":"5629","article-title":"Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes","volume":"53","author":"Chang","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.025_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1084\/jem.155.1.276","article-title":"In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration","volume":"155","author":"Ozer","year":"1982","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2019.11.025_bib21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s12885-016-2597-2","article-title":"Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators","volume":"16","author":"Wu","year":"2016","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2019.11.025_bib22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00262-001-0237-3","article-title":"Th2\/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model","volume":"50","author":"Matar","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2019.11.025_bib23","article-title":"Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2019.11.025_bib24","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1008866","article-title":"Trial Watch: immunogenic cell death inducers for anticancer chemotherapy","volume":"4","author":"Pol","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2019.11.025_bib25","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/0008-5472.CAN-11-3380","article-title":"VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression","volume":"72","author":"Doloff","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.025_bib26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1005521","article-title":"Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory","volume":"4","author":"Wu","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2019.11.025_bib27","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2019.11.025_bib28","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.V95.6.2024","article-title":"Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer","volume":"95","author":"Schiavoni","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2019.11.025_bib29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1593\/neo.131910","article-title":"Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression","volume":"16","author":"Chen","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2019.11.025_bib30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.canlet.2014.07.033","article-title":"Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model","volume":"353","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2019.11.025_bib31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12885-015-1358-y","article-title":"Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts","volume":"15","author":"Doloff","year":"2015","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2019.11.025_bib32","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1158\/1078-0432.CCR-12-3666","article-title":"Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy","volume":"19","author":"Moschella","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.025_bib33","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2019.11.025_bib34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ni.2686","article-title":"IFN-beta-specific signaling via a unique IFNAR1 interaction","volume":"14","author":"Kaur","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2019.11.025_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cytogfr.2017.06.008","article-title":"The added value of type I interferons to cytotoxic treatments of cancer","volume":"36","author":"Bracci","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2019.11.025_bib36","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.025_bib37","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.025_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00262-005-0029-2","article-title":"Importance of signaling via the IFN-alpha\/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor","volume":"55","author":"Mokyr","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2019.11.025_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF03159989","article-title":"Ganglioside distribution in murine neural tumors","volume":"17","author":"Seyfried","year":"1992","journal-title":"Mol. Chem. Neuropathol."},{"key":"10.1016\/j.canlet.2019.11.025_bib40","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1158\/0008-5472.CAN-04-4103","article-title":"Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse","volume":"65","author":"Pass","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.025_bib41","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/0008-5472.CAN-10-3242","article-title":"Antiangiogenesis enhances intratumoral drug retention","volume":"71","author":"Ma","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.11.025_bib42","doi-asserted-by":"crossref","first-page":"26496","DOI":"10.18632\/oncotarget.8420","article-title":"Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs","volume":"7","author":"Ranoa","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2019.11.025_bib43","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1046\/j.1432-1033.2003.03530.x","article-title":"Deadenylation of interferon-beta mRNA is mediated by both the AU-rich element in the 3'-untranslated region and an instability sequence in the coding region","volume":"270","author":"Paste","year":"2003","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.canlet.2019.11.025_bib44","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbrc.2012.09.144","article-title":"Analysis of interferon-beta mRNA stability control after poly(I:C) stimulation using RNA metabolic labeling by ethynyluridine","volume":"428","author":"Abe","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2019.11.025_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1443.020","article-title":"Toll-like receptor and RIG-I-like receptor signaling","volume":"1143","author":"Kawai","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.canlet.2019.11.025_bib46","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2019.11.025_bib47","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2019.11.025_bib48","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10495-008-0303-9","article-title":"Immunogenic cell death modalities and their impact on cancer treatment","volume":"14","author":"Kepp","year":"2009","journal-title":"Apoptosis"},{"key":"10.1016\/j.canlet.2019.11.025_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112456","article-title":"cGAS\/STING pathway in cancer: Jekyll and Hyde story of cancer immune response","volume":"18","author":"Bose","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2019.11.025_bib50","doi-asserted-by":"crossref","first-page":"711","DOI":"10.3389\/fimmu.2018.00711","article-title":"Targeting cytosolic nucleic acid-sensing pathways for cancer immunotherapies","volume":"9","author":"Iurescia","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2019.11.025_bib51","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2019.11.025_bib52","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2019.11.025_bib53","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1158\/2326-6066.CIR-16-0365","article-title":"The tumor microenvironment regulates sensitivity of murine lung tumors to PD-1\/PD-L1 antibody blockade","volume":"5","author":"Li","year":"2017","journal-title":"Canc. Immunol. Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519305804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519305804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:46:15Z","timestamp":1759592775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519305804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":53,"alternative-id":["S0304383519305804"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.11.025","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}